

# Pharmacogenomics Testing

**Humana**

Medicaid Medical Coverage Policy

Original Effective Date: 04/01/2025

Effective Date: 04/21/2025

Review Date: 04/01/2025

Policy Number: HUM-2240-000

Line of Business: Medicaid

State(s): FL, IN, KY, OH, SC, VA

## Table of Contents

[Description](#)

[Coverage Limitations](#)

[References](#)

[Coverage Determination](#)

[Coding Information](#)

[Change Summary](#)

### Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

## Description

**Pharmacogenomics testing** is laboratory testing which has the potential to determine how an individual's genetic factors may affect the safety and effectiveness of that individual's response to a specific medication. The goal of pharmacogenomics testing is to reduce the incidence of adverse medication reactions while improving an individual's positive response to the medication. Additionally, some tests may help provide information on how well a specific treatment may work for an individual.

## Coverage Determination

### **DPYD Genotype Testing**

Humana members may be eligible under the Plan for **DPYD genotype testing (81232)** for either of the following indications:

- Guide medication dosing when performed prior to the initiation of fluoropyrimidine medication therapy (eg, capecitabine, fluorouracil)<sup>8,39,52</sup>; **OR**
- Severe or unexpected toxicity from fluoropyrimidine medication therapy (eg, capecitabine, fluorouracil)<sup>39</sup>

**NUDT15 and TPMT Genotype Testing**

Humana members may be eligible under the Plan for **NUDT15 (81306) and/or TPMT (84433) genotype testing** for either of the following indications:

- Guide medication dosing when performed prior to the initiation of thiopurine medication therapy (eg, azathioprine, mercaptopurine, thioguanine)<sup>1,12,32,34,52</sup>; **OR**
- Severe toxicity from thiopurine medication therapy (eg, azathioprine, mercaptopurine, thioguanine)<sup>34</sup>

**Coverage Limitations**

Humana members may **NOT** be eligible under the Plan for the following pharmacogenomics testing:

- Cytochrome P450 1A2 Genotype (0031U)
- EffectiveRX Comprehensive Panel (0438U)
- Genomind Pharmacogenetics Report – Full (0423U)
- *IFNL3* genotype testing (81283)
- MindX One Blood Test – Anxiety (0437U)
- Psych HealthPGx Panel (0173U)
- RightMed Comprehensive Test (0349U)
- RightMed Comprehensive Test Excludes F2 and F5 (0348U)
- RightMed Gene Report (0350U)
- RightMed Gene Test Excludes F2 and F5 (0434U)
- RightMed Oncology Medication Report (0461U)
- Serotonin Receptor Genotype (0033U)
- Tempus nP (0419U)

A review of the current medical literature shows that there is **no evidence** to determine that these services are standard medical treatments. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of these services in clinical management.

Humana members may **NOT** be eligible under the Plan for the following pharmacogenomics testing:

- ChemoFx Assay (81535/81536)<sup>5,26,33,40</sup>
- CNT (CEP72, NUDT15 and TPMT) Genotyping Panel (0286U)<sup>28</sup>
- GeneSight Psychotropic test (0345U)
- Genomind Professional PGx Express CORE (0175U)<sup>14,22,30,41,49,50</sup>
- IDgenetix (0411U)
- Mayo Clinic Catechol-O-Methyltransferase (COMT) Genotype (0032U)<sup>10</sup>
- *SLCO1B1* genotype testing (81328)<sup>23,35</sup>
- *TYMS* genotype testing (81346)<sup>8,39</sup>

These are considered experimental/investigational as they are not identified as widely used and generally accepted for any other proposed uses as reported in nationally recognized peer-reviewed medical literature published in the English language.

## Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81232	DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)	
81283	IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant	
81306	NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)	
81328	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)	
81346	TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)	
81535	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination	
81536	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)	
84433	Thiopurine S-methyltransferase (TPMT)	
0031U	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)	

0033U	HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G])	
0173U	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes	
0175U	Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes	
0286U	CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants	
0345U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	
0348U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes	
0349U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions	
0350U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes	
0411U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	
0419U	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype	
0423U	Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition	
0434U	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes	

0437U	Psychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score	
0438U	Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions	
0461U	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

## References

1. American Gastroenterological Association (AGA). American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <https://gastro.org>. Published September 2017.
2. Association for Diagnostics & Laboratory Medicine (ADLM). Practice Guideline. Using clinical laboratory tests to monitor drug therapy in pain management patients. <https://myadlm.org>. Published January 1, 2017.
3. Association for Molecular Pathology (AMP). DPYD genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. <https://amp.org>. Published October 2024.
4. Association for Molecular Pathology (AMP). TPMT and NUDT15 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. <https://amp.org>. Published October 2022.

5. Burstein HJ, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. *J Clin Oncol*. 2011;29(24):3328-3330.
6. Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. <https://cpicpgx.org>. Updated December 2016.
7. Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. <https://cpicpgx.org>. Published April 2023.
8. Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. <https://cpicpgx.org>. Published October 2017. Updated March 2024.
9. Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for IFNL3 (IL28B) genotype and PEG interferon- $\alpha$ -based regimens. <https://cpicpgx.org>. Published February 2014.
10. Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. <https://cpicpgx.org>. Published December 2020.
11. Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. <https://cpicpgx.org>. Published January 2022.
12. Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. <https://cpicpgx.org>. Published November 2018.
13. ECRI Institute. ECRIgene. Thiopurine S-Methyltransferase (TPMT) Genotype (Quest Diagnostics Inc) to guide medication selection for patients with adverse responses to mercaptopurine or azathioprine. <https://home.ecri.org>. Published June 2020.
14. ECRI Institute. ECRIgene Genetic Test Product Brief. Genomind Professional PGx Express (Genomind, Inc.) to inform medication selection for treating psychiatric disorders. <https://home.ecri.org>. Published June 2020.
15. ECRI Institute. Genetic Test Assessment. GeneSight Psychotropic (Myriad Genetics, Inc.) to inform medication selection for treating major depressive disorder. <https://home.ecri.org>. Published August 2020.

16. ECRI Institute. Genetic Test Assessment. IDgenetix (Castle Biosciences, Inc.) for guiding medication selection for patients with mental health disorders. <https://home.ecri.org>. Published June 2023.
17. ECRI Institute. Genetic Test Assessment. RightMed (OneOme, LLC) for guiding common prescription medications selections and dosage. <https://home.ecri.org>. Published August 2021.
18. Hayes, Inc. Clinical Utility Evaluation. Pharmacogenetic testing for opioid treatment for pain – OPRM1 and COMT variants. <https://evidence.hayesinc.com>. Published December 13, 2019. Updated October 24, 2022.
19. Hayes, Inc. Clinical Utility Evaluation. Pharmacogenetic and pharmacogenomic testing for opioid treatment for pain in adults – selected single-gene variants and pharmacogenomic panels. <https://evidence.hayesinc.com>. Published December 11, 2019. Updated October 26, 2022.
20. Hayes, Inc. Clinical Utility Evaluation. Pharmacogenetic and pharmacogenomic testing to improve outcomes related to opioid use disorder. <https://evidence.hayesinc.com>. Published April 27, 2020. Updated June 30, 2023.
21. Hayes, Inc. Clinical Utility Evaluation. Pharmacogenetic testing to guide codeine or tramadol prescribing for pain in pediatric patients. <https://evidence.hayesinc.com>. Published February 19, 2020. Updated March 30, 2023.
22. Hayes, Inc. Clinical Utility Evaluation. Pharmacogenetic testing selected mental health conditions. <https://evidence.hayesinc.com>. Published December 6, 2021. Updated December 9, 2024.
23. Hayes, Inc. GTE Clinical Utility Report. SLCO1B1 pharmacogenomic genotyping for statin dosing or selection. <https://evidence.hayesinc.com>. Published August 4, 2016. Updated May 19, 2020.
24. Hayes, Inc. GTE Report. TheraGuide 5-FU (Myriad Genetic Laboratories Inc.) for predicting toxicity to 5-fluorouracil (5-FU) / capecitabine-based chemotherapy. <https://evidence.hayesinc.com>. Published May 5, 2009. Updated May 14, 2013.
25. Hayes, Inc. Hayes Brief. Genetic testing for thiopurine s-methyltransferase (TPMT) activity for prediction of response to thiopurine drug therapy for inflammatory bowel disease. <https://evidence.hayesinc.com>. Published December 19, 2006. Updated February 5, 2009.
26. Hayes, Inc. Molecular Test Assessment. ChemoFx Assay (Helomics). <https://evidence.hayesinc.com>. Published December 2, 2020. Updated December 11, 2023.
27. Hayes, Inc. Molecular Test Assessment. GeneSight Psychotropic (Assurex Health Inc./Myriad Neuroscience). <https://evidence.hayesinc.com>. Published December 10, 2021. Updated September 17, 2024.
28. Hayes, Inc. Precision Medicine Research Brief. CNT (CEP72, NUDT15, and TPMT) Panel (RPRD Diagnostics LLC). <https://evidence.hayesinc.com>. Published December 4, 2023.

29. Hayes, Inc. Precision Medicine Research Brief. The RightMed Test (OneOme LLC). <https://evidence.hayesinc.com>. Published March 25, 2024.
30. International Society of Psychiatric Genetics (ISPG). Genetic testing statement: genetic testing and psychiatric disorders. <https://ispg.net>. Updated March 11, 2019.
31. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium: NUDT15, TPMT. <https://nccn.org>. Updated 2025.
32. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute lymphoblastic leukemia. <https://nccn.org>. Updated December 20, 2024.
33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. <https://nccn.org>. Updated March 5, 2025.
34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Pediatric acute lymphoblastic leukemia. <https://nccn.org>. Updated March 17, 2025.
35. National Lipid Association (NLA). Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. <https://lipid.org>. Published 2023.
36. UpToDate, Inc. Benefits and risks of caffeine and caffeinated beverages. <https://uptodate.com>. Updated February 2025.
37. UpToDate, Inc. Chronic immunotherapy for myasthenia gravis. <https://uptodate.com>. Updated February 17, 2025.
38. UpToDate, Inc. Clinical presentation and risk factors for chemotherapy-associated diarrhea, constipation, and intestinal perforation. <https://uptodate.com>. Updated February 2025.
39. UpToDate, Inc. Dosing of anticancer agents in adults. <https://uptodate.com>. Updated February 2025.
40. UpToDate, Inc. First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer. <https://uptodate.com>. Updated February 28, 2025.
41. UpToDate, Inc. Major depressive disorder in adults: initial treatment with antidepressants. <https://uptodate.com>. Updated February 2025.
42. UpToDate, Inc. Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: platinum-sensitive disease. <https://uptodate.com>. Updated February 2025.
43. UpToDate, Inc. Overview of azathioprine and mercaptopurine use in inflammatory bowel disease. <https://uptodate.com>. Updated February 2025.

44. UpToDate, Inc. Overview of pharmacogenomics. <https://uptodate.com>. Updated February 2025.
45. UpToDate, Inc. Pharmacology and side effects of azathioprine when used in rheumatic diseases. <https://uptodate.com>. Updated February 2025.
46. UpToDate, Inc. Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: post-remission management. <https://uptodate.com>. Updated February 10, 2025.
47. UpToDate, Inc. Statin muscle-related adverse events. <https://uptodate.com>. Updated February 2025.
48. UpToDate, Inc. Thiopurines: pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease. <https://uptodate.com>. Updated February 24, 2025.
49. UpToDate, Inc. Unipolar depression in adults: choosing treatment for resistant depression. <https://uptodate.com>. Updated February 2025.
50. US Department of Veterans Affairs (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. <https://healthquality.va.gov>. Published 2022.
51. US Department of Veterans Affairs (VA/DoD). VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain. <https://healthquality.va.gov>. Published 2022.
52. US Food & Drug Administration (FDA). Table of pharmacogenetic associations. <https://fda.gov>. Updated October 26, 2022.

## Change Summary

04/01/2025 New Policy.